BACKGROUND: Although it has been demonstrated that the neuronal intermediate filament alpha-internexin (INA) is closely related to 1p19q codeletion in gliomas, its prognostic and predictive value has not yet been confirmed in a prospective trial. The authors of this report assessed the prognostic significance of INA expression and its correlation with relevant clinical and molecular characteristics in the prospective, randomized European Organization for Research and Treatment of Cancer (EORTC) 26951 trial of adjuvant procarbazine, lomustine, and vincristine (PCV) in patients with anaplastic oligodendroglial tumors (AOTs). METHODS:INA immunohistochemistry expressionin tumors from 92 patients who were included in the EORTC 26951 trial was analyzed independently by 2 observers and was correlated with relevant clinical characteristics, including progression-free survival (PFS) and overall survival (OS), and with molecular features, including 1p/19q codeletion, isocitrate dehydrogenase 1 and 2 gene (IDH1/IDH2) mutation, and O-6 methylguanine-DNA methyltransferase (MGMT) promoter methylation status. RESULTS:INA expression was observed in 33 tumors and was strongly correlated with 1p/19q codeletion, IDH1 mutations, and MGMT promoter methylation. It was associated with significantly better PFS and OS independent of the treatment received. By using Cox proportional hazard modeling for OS with stepwise selection, INA expression, patient age, and performance status were identified as independent prognostic factors. The results indicated that INA expression may have an impact on the efficacy of combined radiotherapy plus PCV. CONCLUSIONS: In a homogeneously treated group of patients with grade III AOTs, INA expression had strong favorable prognostic significance for OS and may have predictive value for sensitivity to chemotherapy.
RCT Entities:
BACKGROUND: Although it has been demonstrated that the neuronal intermediate filament alpha-internexin (INA) is closely related to 1p19q codeletion in gliomas, its prognostic and predictive value has not yet been confirmed in a prospective trial. The authors of this report assessed the prognostic significance of INA expression and its correlation with relevant clinical and molecular characteristics in the prospective, randomized European Organization for Research and Treatment of Cancer (EORTC) 26951 trial of adjuvant procarbazine, lomustine, and vincristine (PCV) in patients with anaplastic oligodendroglial tumors (AOTs). METHODS: INA immunohistochemistry expression in tumors from 92 patients who were included in the EORTC 26951 trial was analyzed independently by 2 observers and was correlated with relevant clinical characteristics, including progression-free survival (PFS) and overall survival (OS), and with molecular features, including 1p/19q codeletion, isocitrate dehydrogenase 1 and 2 gene (IDH1/IDH2) mutation, and O-6 methylguanine-DNA methyltransferase (MGMT) promoter methylation status. RESULTS: INA expression was observed in 33 tumors and was strongly correlated with 1p/19q codeletion, IDH1 mutations, and MGMT promoter methylation. It was associated with significantly better PFS and OS independent of the treatment received. By using Cox proportional hazard modeling for OS with stepwise selection, INA expression, patient age, and performance status were identified as independent prognostic factors. The results indicated that INA expression may have an impact on the efficacy of combined radiotherapy plus PCV. CONCLUSIONS: In a homogeneously treated group of patients with grade III AOTs, INA expression had strong favorable prognostic significance for OS and may have predictive value for sensitivity to chemotherapy.
Authors: Walter Taal; Carin C D van der Rijt; Winand N M Dinjens; Peter A E Sillevis Smitt; Agnes A A C M Wertenbroek; Jacoline E C Bromberg; Irene van Heuvel; Johan M Kros; Martin J van den Bent Journal: J Neurooncol Date: 2014-10-26 Impact factor: 4.130
Authors: D Schult; A Hölsken; M Buchfelder; S-M Schlaffer; S Siegel; I Kreitschmann-Andermahr; R Fahlbusch; R Buslei Journal: Pituitary Date: 2015-08 Impact factor: 4.107
Authors: Simon Schimmack; Ben Lawrence; Bernhard Svejda; Daniele Alaimo; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Mark Kidd; Irvin Modlin Journal: Cancer Date: 2011-10-11 Impact factor: 6.860
Authors: Manmeet S Ahluwalia; Hao Xie; Saurabh Dahiya; Nooshin Hashemi-Sadraei; David Schiff; Paul G Fisher; Marc C Chamberlain; Susan Pannullo; Herbert B Newton; Cathy Brewer; Laura Wood; Richard Prayson; Paul Elson; David M Peereboom Journal: J Neurooncol Date: 2014-12-23 Impact factor: 4.130
Authors: J S Frenel; C Leux; D Loussouarn; A-G Le Loupp; F Leclair; M Aumont; A Mervoyer; S Martin; M G Denis; M Campone Journal: J Neurooncol Date: 2013-05-17 Impact factor: 4.506